Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deep Brain Stimulation | 8 | 2017 | 40 | 1.640 |
Why?
|
| Electrodes, Implanted | 3 | 2017 | 21 | 0.570 |
Why?
|
| Parkinson Disease | 12 | 2013 | 826 | 0.480 |
Why?
|
| Anterior Thalamic Nuclei | 2 | 2010 | 3 | 0.390 |
Why?
|
| Epilepsy | 2 | 2010 | 64 | 0.370 |
Why?
|
| Ventral Thalamic Nuclei | 2 | 2017 | 2 | 0.350 |
Why?
|
| Genetic Therapy | 6 | 2014 | 80 | 0.350 |
Why?
|
| Dentate Gyrus | 1 | 2009 | 6 | 0.340 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2009 | 24 | 0.340 |
Why?
|
| Brain | 5 | 2017 | 1639 | 0.320 |
Why?
|
| Essential Tremor | 1 | 2008 | 5 | 0.320 |
Why?
|
| Neurons | 3 | 2009 | 310 | 0.300 |
Why?
|
| Hypothalamic Area, Lateral | 1 | 2007 | 2 | 0.300 |
Why?
|
| Dependovirus | 3 | 2014 | 37 | 0.280 |
Why?
|
| Postoperative Complications | 2 | 2009 | 866 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 1145 | 0.240 |
Why?
|
| Obesity | 1 | 2007 | 278 | 0.240 |
Why?
|
| Neurturin | 3 | 2010 | 23 | 0.230 |
Why?
|
| Stereotaxic Techniques | 4 | 2017 | 14 | 0.230 |
Why?
|
| Adrenal Medulla | 4 | 1997 | 7 | 0.220 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 336 | 0.210 |
Why?
|
| Genetic Vectors | 4 | 2014 | 55 | 0.190 |
Why?
|
| Transplantation, Heterotopic | 3 | 1997 | 7 | 0.180 |
Why?
|
| Caudate Nucleus | 3 | 1997 | 11 | 0.170 |
Why?
|
| Nerve Growth Factor | 2 | 2014 | 33 | 0.170 |
Why?
|
| Putamen | 2 | 2010 | 21 | 0.170 |
Why?
|
| Male | 15 | 2017 | 14107 | 0.170 |
Why?
|
| Postoperative Period | 3 | 2017 | 312 | 0.150 |
Why?
|
| Peripheral Nerves | 1 | 1997 | 18 | 0.150 |
Why?
|
| Humans | 19 | 2017 | 26227 | 0.150 |
Why?
|
| Globus Pallidus | 3 | 2017 | 11 | 0.140 |
Why?
|
| Corpus Striatum | 3 | 2008 | 61 | 0.140 |
Why?
|
| Middle Aged | 10 | 2017 | 8585 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2010 | 1735 | 0.130 |
Why?
|
| Dopamine | 3 | 2007 | 79 | 0.130 |
Why?
|
| Nerve Growth Factors | 2 | 2010 | 35 | 0.130 |
Why?
|
| Substantia Nigra | 3 | 2007 | 113 | 0.130 |
Why?
|
| Treatment Outcome | 7 | 2015 | 3381 | 0.130 |
Why?
|
| Animals | 8 | 2013 | 3388 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 2 | 2009 | 149 | 0.130 |
Why?
|
| Analysis of Variance | 3 | 2012 | 252 | 0.120 |
Why?
|
| Female | 12 | 2017 | 14499 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2014 | 207 | 0.120 |
Why?
|
| Parkinsonian Disorders | 2 | 2009 | 218 | 0.120 |
Why?
|
| Movement Disorders | 1 | 2015 | 89 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 676 | 0.120 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 563 | 0.110 |
Why?
|
| Adult | 7 | 2015 | 7437 | 0.110 |
Why?
|
| Electric Stimulation Therapy | 2 | 2010 | 41 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 716 | 0.110 |
Why?
|
| Colon | 1 | 2013 | 137 | 0.100 |
Why?
|
| Intraoperative Period | 1 | 2012 | 25 | 0.100 |
Why?
|
| Skull | 1 | 2012 | 23 | 0.100 |
Why?
|
| Observer Variation | 1 | 2012 | 93 | 0.100 |
Why?
|
| alpha-Synuclein | 1 | 2013 | 121 | 0.100 |
Why?
|
| Cell Count | 2 | 2009 | 75 | 0.100 |
Why?
|
| Microelectrodes | 2 | 2009 | 18 | 0.100 |
Why?
|
| Functional Laterality | 2 | 2010 | 62 | 0.090 |
Why?
|
| Subthalamic Nucleus | 2 | 2017 | 20 | 0.090 |
Why?
|
| Radiography | 1 | 2012 | 614 | 0.090 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2009 | 5 | 0.090 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2009 | 6 | 0.090 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2009 | 8 | 0.090 |
Why?
|
| Antiparkinson Agents | 2 | 2002 | 65 | 0.080 |
Why?
|
| Pyramidal Cells | 1 | 2009 | 29 | 0.080 |
Why?
|
| Cell Survival | 1 | 2009 | 111 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 73 | 0.080 |
Why?
|
| Blepharospasm | 1 | 2009 | 1 | 0.080 |
Why?
|
| Torticollis | 1 | 2009 | 12 | 0.080 |
Why?
|
| Transgenes | 1 | 2008 | 13 | 0.080 |
Why?
|
| Medical Records | 1 | 2008 | 30 | 0.080 |
Why?
|
| Tyrosine 3-Monooxygenase | 4 | 2013 | 49 | 0.080 |
Why?
|
| Alzheimer Disease | 2 | 2014 | 2062 | 0.080 |
Why?
|
| Drinking | 1 | 2007 | 4 | 0.070 |
Why?
|
| Eating | 1 | 2007 | 47 | 0.070 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2007 | 10 | 0.070 |
Why?
|
| MPTP Poisoning | 1 | 2007 | 13 | 0.070 |
Why?
|
| Neostriatum | 1 | 2007 | 13 | 0.070 |
Why?
|
| Aged | 5 | 2015 | 8749 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 317 | 0.070 |
Why?
|
| Autopsy | 1 | 2008 | 340 | 0.070 |
Why?
|
| Rats | 1 | 2007 | 598 | 0.060 |
Why?
|
| Inflammation | 1 | 2008 | 264 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 1997 | 280 | 0.060 |
Why?
|
| Motor Activity | 3 | 2010 | 314 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2005 | 9 | 0.060 |
Why?
|
| Prosencephalon | 1 | 2005 | 8 | 0.060 |
Why?
|
| Brain Tissue Transplantation | 2 | 1997 | 18 | 0.060 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1997 | 25 | 0.060 |
Why?
|
| Adolescent | 1 | 2009 | 2078 | 0.060 |
Why?
|
| Young Adult | 1 | 2009 | 1886 | 0.060 |
Why?
|
| Phonation | 1 | 2003 | 4 | 0.050 |
Why?
|
| Speech Disorders | 1 | 2003 | 11 | 0.050 |
Why?
|
| Electric Stimulation | 1 | 2003 | 48 | 0.050 |
Why?
|
| Speech | 1 | 2003 | 22 | 0.050 |
Why?
|
| Respiration | 1 | 2003 | 32 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 935 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 84 | 0.040 |
Why?
|
| Aging | 2 | 2007 | 1536 | 0.040 |
Why?
|
| Registries | 2 | 1991 | 177 | 0.040 |
Why?
|
| Transplantation, Autologous | 2 | 1997 | 160 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2010 | 399 | 0.040 |
Why?
|
| Time Factors | 2 | 2013 | 1382 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 26 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 35 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2017 | 37 | 0.040 |
Why?
|
| Macaca mulatta | 2 | 2007 | 56 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 2 | 2010 | 23 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2014 | 1221 | 0.030 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2014 | 10 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 217 | 0.030 |
Why?
|
| Vagus Nerve | 1 | 2013 | 13 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2013 | 12 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 11 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 12 | 0.030 |
Why?
|
| Permeability | 1 | 2013 | 116 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1993 | 6 | 0.030 |
Why?
|
| Thalamus | 1 | 1993 | 16 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 239 | 0.030 |
Why?
|
| Mesencephalon | 1 | 1993 | 26 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 125 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 370 | 0.030 |
Why?
|
| Chromogranins | 1 | 1991 | 3 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1991 | 11 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 685 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2010 | 14 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 1277 | 0.020 |
Why?
|
| Dysarthria | 1 | 2009 | 2 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2009 | 15 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 23 | 0.020 |
Why?
|
| Motor Skills | 1 | 2009 | 52 | 0.020 |
Why?
|
| Memory Disorders | 1 | 2010 | 164 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 112 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 215 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 133 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2009 | 168 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 12 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2006 | 9 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 2006 | 13 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2007 | 42 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 27 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2006 | 71 | 0.020 |
Why?
|
| Depression | 1 | 2010 | 407 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1342 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2005 | 6 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2006 | 283 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2005 | 56 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 38 | 0.020 |
Why?
|
| Speech Articulation Tests | 1 | 2003 | 3 | 0.010 |
Why?
|
| Acoustics | 1 | 2003 | 19 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 2003 | 47 | 0.010 |
Why?
|
| Haplorhini | 1 | 2002 | 9 | 0.010 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2002 | 18 | 0.010 |
Why?
|
| Lentivirus | 1 | 2002 | 11 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 2002 | 16 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 55 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 73 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 378 | 0.010 |
Why?
|
| Cognition | 1 | 2005 | 1287 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1997 | 287 | 0.010 |
Why?
|
| Data Collection | 1 | 1991 | 91 | 0.010 |
Why?
|
| Chromogranin A | 1 | 1991 | 9 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1990 | 11 | 0.010 |
Why?
|
| Canada | 1 | 1990 | 49 | 0.010 |
Why?
|
| Levodopa | 1 | 1990 | 47 | 0.010 |
Why?
|
| Prognosis | 1 | 1991 | 758 | 0.010 |
Why?
|
| Chicago | 1 | 1990 | 846 | 0.000 |
Why?
|
| United States | 1 | 1990 | 1991 | 0.000 |
Why?
|